Pfizer publishes the final results of its Coronavirus Covid-19 vaccine trial. It turns out to be very effective but now there is another huge problem.
Over the past weeks we have witnessed encouraging news with the revelation that the experimental vaccine against Coronavirus Covid-19 from Pfizer would be quite effective.
The latest tests projected a 95% response among patients infected with SARS-CoV-2 who took the vaccine and saw some substantial improvement in their health.
However, this vaccine, called BNT162b2, you have a considerable logistics problem: it should always be kept at -70 degrees Celsius.
A distribution nightmare
The pharmaceutical Has published the latest results of your tests. At the same time, together with their BioNTech partners, they have detailed the details of their first distribution pilot test.
Where the mechanism and transfer network will be evaluated to be able to carry the doses from one point to another maintaining the low temperature that it demands.
For this pilot the experimental vaccine will be taken to four states of the American union: Rhode Island, Texas, New Mexico and Tennessee.
This would only be an evaluation and not a first round of distribution. So these localities would not have any privilege over others in the country:
We are hopeful that the results of this pilot vaccine delivery program will serve as a model for other US states and international governments as they prepare to implement effective COVID-19 vaccine programs.
The Pfizer vaccine must be transported and stored permanently at a temperature of -70 ° C. This represents an important change with respect to other vaccines that usually require only a temperature of 2 to 8 ° C for transport.
Each of the States selected for the shipping test has unique qualities that will help define guidelines for improving the system.
The government of that country already has a contract for 100 million doses for months. So it better work.